Wojciech Jurczak, MD, PhD, head of the Department of Oncology at Maria Sklodowska-Curie National Research Institute of Oncology, discusses the changing therapy landscape for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Wojciech Jurczak, MD, PhD, head of the Department of Oncology at Maria Sklodowska-Curie National Research Institute of Oncology, discussed the changing therapy landscape for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Transcript
How might the findings of the phase 2 L-MIND study help inform clinical practice and treatment decisions for patients with relapsed or refractory DLBCL?
The perspective of relapsing/refractory diffuse large B-cell lymphoma is changing evidently. We have the dusk of classical chemotherapy as we know, including high-dose chemo, and transplant is gradually replaced by a targeted chemotherapy, molecular targeted agents, and, last but not least, immunotherapy. It is difficult to use molecular targeted agents with the present diagnostic methods—it should be noticed that even at this EHA [European Hematology Association annual meeting], there were some data on CDK9 inhibitors. The targeted chemotherapy is widely used, but what's most important is immunotherapy.
Now, the CAR [chimeric antigen receptor] T cells are approved in the third line and now are being moved to the second line of therapy. The targeted chemotherapy approved in the second line after the POLARIX study is gradually moved to the first line, with immunities like [the] TAFA-LEN [tafasitamab plus lenalidomide] regimen being reserved for the patients who are not eligible for the CAR T-cell therapies either because of age, comorbidities, or logistical problems. As this is a regimen which is excellently tolerated, we can still offer it to the majority of elderly populations, which we do not like to treat with a more harsh Pola-BR regimen, including targeted chemotherapy [polatuzumab vedotin and rituximab] together with bendamustine.
Forging a Patient-Centric Path to Revolutionize and Redefine Value-Based Care
April 30th 2024Optum Life Sciences and Takeda Pharmaceuticals are partnering on an innovative virtual care pilot program for inflammatory bowel disease meant to both continue the mission of the current value-based health care landscape and raise the bar for personalized care delivery optimization.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen